Number of the records: 1
Design and rationale of the EMPA-VISION trial: Investigating the metabolic effects of empagliflozin in patients with heart failure
Title Design and rationale of the EMPA-VISION trial: Investigating the metabolic effects of empagliflozin in patients with heart failure Author Hundertmark M. Co-authors Agbaje O. Coleman R. George J. Grempler R. Holman R. Lamlum H. Lee J. Milton J. Niessen H. Rider O. Rodgers C. Valkovič Ladislav 1986 SAVMER - Ústav merania SAV SCOPUS RID ORCID Wicks E. Mahmod M. Neubauer S. Source document ESC Heart Failure. Vol. 8, no. 4 (2021), p. 2580-2590 Language eng - English Document kind rozpis článkov z periodík (rbx) Citations THIRUNAVUKARASU, S. - JEX, N. - CHOWDHARY, A. - UL HASSAN, I. - STRAW, S. - CRAVEN, T.P. - GORECKA, M. - BROADBENT, D. - SWOBODA, P. - WITTE, K.K. - CUBBON, R.M. - XUE, H. - KELLMAN, P. - GREENWOOD, J.P. - PLEIN, S. - LEVELT, E. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. In DIABETES. ISSN 0012-1797, 2021, vol. 70, no. 12, p. 2810-2822. Dostupné na: https://doi.org/10.2337/db21-0270. MORDI, I.R. - LANG, C.C. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors. In HEART FAILURE CLINICS. ISSN 1551-7136, OCT 2022, vol. 18, no. 4, p. 529-538. Dostupné na: https://doi.org/10.1016/j.hfc.2022.03.004. SELVARAJ, S. - FU, Z.X. - JONES, P. - KWEE, L.C. - WINDSOR, S.L. - ILKAYEVA, O. - NEWGARD, C.B. - MARGULIES, K.B. - HUSAIN, M. - INZUCCHI, S.E. - MCGUIRE, D.K. - PITT, B. - SCIRICA, B.M. - LANFEAR, D.E. - NASSIF, M.E. - JAVAHERI, A. - MENTZ, R.J. - KOSIBOROD, M.N. - SHAH, S.H. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. In CIRCULATION. ISSN 0009-7322, SEP 13 2022, vol. 146, no. 11, p. 808-818. Dostupné na: https://doi.org/10.1161/CIRCULATIONAHA.122.060402. SANTOS-GALLEGO, C.G. - MAYR, M. - BADIMON, J. SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism. In CIRCULATION. ISSN 0009-7322, SEP 13 2022, vol. 146, no. 11, p. 819-821. Dostupné na: https://doi.org/10.1161/CIRCULATIONAHA.122.060805. YIN, Z.W. - ZHENG, H.Z. - GUO, Z.H. Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. In FRONTIERS IN CARDIOVASCULAR MEDICINE. ISSN 2297-055X, MAY 18 2022, vol. 9. Dostupné na: https://doi.org/10.3389/fcvm.2022.902923. HERNANDEZ, M. - SULLIVAN, R.D. - MCCUNE, M.E. - REED, G.L. - GLADYSHEVA, I.P. Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. In DIAGNOSTICS. APR 2022, vol. 12, no. 4. Dostupné na: https://doi.org/10.3390/diagnostics12040989. VARADHAN, A. - STEPHAN, K. - GUPTA, R. - VYAS, A.V. - RANCHAL, P. - ARONOW, W.S. - HAWWA, N. - LANIER, G.M. Growing role of SGLT2i in heart failure: evidence from clinical trials. In EXPERT REVIEW OF CLINICAL PHARMACOLOGY. ISSN 1751-2433, FEB 1 2022, vol. 15, no. 2, p. 147-159. Dostupné na: https://doi.org/10.1080/17512433.2022.2051480. SCHWITTER, J. Getting Deeper Insight by Hyperpolarization: The Multilevel Assessment of Myocardial Infarction by Adding Hyperpolarized sup13/supC-Carbon-CMR. In JACC: CARDIOVASCULAR IMAGING, 2022, vol. 15, no. 12, p. 2065-2068. ISSN 1936-878X. Dostupné na: https://doi.org/10.1016/j.jcmg.2022.09.002. MAACK, C. Mechano-energetic defects in heart failure. In HERZ. ISSN 0340-9937, 2023 MAR 2023, vol. 48, no. 2, p. 123-133. Dostupné na: https://doi.org/10.1007/s00059-022-05161-3. PALAIODIMOU, L. - KOKOTIS, P. - ZOMPOLA, C. - PAPAGIANNOPOULOU, G. - BAKOLA, E. - PAPADOPOULOU, M. - ZOUVELOU, V. - PETRAS, D. - VLACHOPOULOS, C. - TSIVGOULIS, G. Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review. In CURRENT NEUROPHARMACOLOGY. ISSN 1570-159X, 2023, vol. 21, no. 3, p. 440-456. Dostupné na: https://doi.org/10.2174/1570159X20666220601124117. GITTO, M. - VILLASCHI, A. - FEDERICI, M. - CONDORELLI, G. - STEFANINI, G.G. The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. In CURRENT PHARMACEUTICAL DESIGN. ISSN 1381-6128, 2023, vol. 29, no. 7, p. 481-493. Dostupné na: https://doi.org/10.2174/1381612829666230217143324. AGUIAR-NEVES, I. - SANTOS-FERREIRA, D. - FONTES-CARVALHO, R. SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier. In REVIEWS IN CARDIOVASCULAR MEDICINE. ISSN 1530-6550, JAN 2023, vol. 24, no. 1. Dostupné na: https://doi.org/10.31083/j.rcm2401001. XIE, Y.F. - WEI, Y.J. - LI, D. - PU, J. - DING, H. - ZHANG, X.W. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. In JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. ISSN 0160-2446, JAN 2023, vol. 81, no. 1, p. 4-14. Dostupné na: https://doi.org/10.1097/FJC.0000000000001380. PISTELLI, L. - PARISI, F. - CORREALE, M. - COCUZZA, F. - CAMPANELLA, F. - DE FERRARI, T. - CREA, P. - DE SARRO, R. - LA COGNATA, O. - CERATTI, S. - RECUPERO, T. - RUOCCO, G. - PALAZZUOLI, A. - IMBALZANO, E. - DATTILO, G. Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy-A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. In JOURNAL OF CLINICAL MEDICINE. JAN 2023, vol. 12, no. 1. Dostupné na: https://doi.org/10.3390/jcm12010379. SONG, C. - HUANG, Z. - CHEN, W. - WANG, F. - CAI, L. - ZHAO, F. - ZHAO, Y. Empagliflozin alleviates cardiac microvascular ischemia/reperfusion injury by maintaining myocardial mitochondrial homeostasis. In NAN FANG YI KE DA XUE XUE BAO / JOURNAL OF SOUTHERN MEDICAL UNIVERSITY, 2023, vol. 43, no. 7, p. 1136-1144. ISSN 1673-4254. Dostupné na: https://doi.org/10.12122/j.issn.1673-4254.2023.07.10. CORREALE, M. - LAMACCHIA, O. - CICCARELLI, M. - DATTILO, G. - TRICARICO, L. - BRUNETTI, N.D. Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. In HEART FAILURE REVIEWS, 2023, vol. 28, no. 3, p. 733-744. ISSN 1382-4147. Dostupné na: https://doi.org/10.1007/s10741-021-10157-y. MUNTEANU, M.A. - SWARNKAR, S. - POPESCU, R.-I. - LUNGU, A. - CIOBOTARU, L. - NICOLAE, C. - TUFANOIU, E. – NANEA, I.T. SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics? In MAEDICA (BUCUR). ISSN 1841-9038, 2023, vol. 18, no. 1, p. 102–110. Dostupné na: https://doi.org/10.26574%2Fmaedica.2023.18.1.102. CHO, D.-H. SGLT2 Inhibitors: Emerging Drugs in Heart Failure. In KOREAN JOURNAL OF MEDICINE. ISSN 1738-9364, 2023, vol. 98, no. 2, p. 59-63. Dostupné na: https://doi.org/10.3904/kjm.2023.98.2.59. DOS SANTOS, J. - DAWSON, S. - CONEFREY, C. - ISAACS, T. - KHANUM, M. - FAISAL, S. - PARAMASIVAN, S. Most UK cardiovascular disease trial protocols feature criteria that exclude ethnic minority participants: a systematic review. In JOURNAL OF CLINICAL EPIDEMIOLOGY. ISSN 0895-4356, MAR 2024, vol. 167. Dostupné na: https://doi.org/10.1016/j.jclinepi.2024.111259. Category ADCA - Scientific papers in foreign journals registered in Current Contents Connect with IF (impacted) Category of document (from 2022) V3 - Vedecký výstup publikačnej činnosti z časopisu Type of document článok Year 2021 Registered in WOS Registered in SCOPUS Registered in CCC DOI 10.1002/ehf2.13406 
article
File name Access Size Downloaded Type License Design and rationale of the EMPA-VISION trial.pdf available 444.2 KB 2 Publisher's version rok CC IF IF Q (best) JCR Av Jour IF Perc SJR SJR Q (best) CiteScore A rok vydania rok metriky IF IF Q (best) SJR SJR Q (best) 2021 2020 4.411 Q2 0.787 Q2
Number of the records: 1